ProfileGDS5678 / 1434135_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 55% 67% 58% 66% 62% 60% 55% 65% 68% 63% 64% 63% 63% 68% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.4392755
GSM967853U87-EV human glioblastoma xenograft - Control 24.0423867
GSM967854U87-EV human glioblastoma xenograft - Control 33.5094358
GSM967855U87-EV human glioblastoma xenograft - Control 43.9592566
GSM967856U87-EV human glioblastoma xenograft - Control 53.6820562
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6640560
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.444855
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.9493565
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.1709868
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.7519263
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.8115464
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.7450563
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.7534363
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.1877368